Viral Vector Vaccine

Modality

Viral vector vaccines typically employ a harmless virus, such as adenovirus, adeno-associated virus, lentivirus, or herpes simplex virus, as the carrier. The target DNA sequence is integrated into the viral vector, allowing for the expression of the target antigen within the body and subsequent activation of the immune response.

Recombinant viral vectors are created by using plasmid DNA containing the gene encoding the antigen as the raw material, which is then transfected into cells and packaged into viruses.

Leveraging a robust process development platform and extensive experience in plasmid DNA production, Yaohai Bio-Pharma offers customers efficient solutions for GMP-grade plasmid DNA production. We are dedicated to meeting the specific needs of our clients, and can adjust our service process accordingly. Our services include the provision of DNA raw materials and sterile drug products at tens of grams scale, as well as comprehensive development and production reports and testing reports.

One-Stop Plasmid DNA Solution of Yaohai Bio-Pharma

Deliverables

Grade

Deliverables

Specification

Applications

non-GMP

Plasmid as material

0.2~10 g (Plasmid DNA)

Preclinical studies,
Analytical method development,
Pre-stability studies,
Formulation development

GMP, Sterile

Plasmid as material

10~100 g (Plasmid DNA)

Investigational new drug (IND),

Clinical trial authorisation (CTA),

Clinical trial supply,

Commercial supply

All Categories

Viral Vector Vaccine

Modality